A clinical trial update was posted on September 18, 2026, regarding a study involving kisspeptin related neuro-reproductive research. The trial, registered as NCT07169136, is titled "Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic Ovary Syndrome (PCOS)." The listed status for this trial is RECRUITING. No phase information was provided in the available record. The study is examining GLP-1 agonist effects in a population of obese adolescent females diagnosed with PCOS, with a focus on neuro-reproductive function, an area in which kisspeptin signaling is often studied. No results have been posted for this trial at this time. The recruiting status indicates that the study is currently enrolling participants but has not yet reported outcomes. Kisspeptin remains classified as an unapproved compound used in research settings. This update reflects only the trial's current registration status and does not include efficacy or safety findings. Readers interested in learning more about the compound's background and general research context can consult the compound overview for further information.
Kisspeptin-Related Trial NCT07169136 Recruiting on GLP-1 in PCOS Adolescents
See the full kisspeptin overview
Source: https://clinicaltrials.gov/study/NCT07169136